贝达药业涨2.00%，成交额2.89亿元，主力资金净流出934.89万元

Core Viewpoint - Benda Pharmaceutical's stock has shown a mixed performance with a year-to-date increase of 7.90%, but a significant decline of 12.97% over the past 60 days, indicating volatility in its market position [1]. Financial Performance - For the period from January to September 2025, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 669 million yuan, with 184 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - The stock's trading activity showed a net outflow of 9.349 million yuan from major funds, with significant buying and selling activity from large orders [1]. Company Overview - Benda Pharmaceutical, established on January 7, 2003, and listed on November 7, 2016, is primarily engaged in the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concepts such as ophthalmology, innovative drugs, and precision medicine [1].